Literature DB >> 9479579

Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

P C Nowell1, J S Moore.   

Abstract

Studies in this laboratory have recently focused on two hemic neoplasms: B cell chronic lymphocytic leukemia (B-CLL) and a T cell disorder, Sézary syndrome. These tumors do not have consistent cytogenetic or molecular genetic alterations, and so we have concentrated on their response to and production of various regulatory cytokines. Although B-CLL cells show variable proliferative responses when exposed to transforming growth factor beta (TGF beta), these cells have consistently shown resistance to the pro-apoptotic effects of this cytokine. Also, interleukin 4 (IL4), IL5, and interferon-gamma (IFN gamma) all show a consistently increased protective effect against apoptosis in B-CLL cells as compared to normal human B cells. Thus, a defect in apoptosis appears to be an important factor in the pathogenesis of CLL. By contrast, the neoplastic T cells of Sézary syndrome show a consistent resistance to the antiproliferative effects of TGF beta, suggesting that aberrant proliferation is more important than apoptosis in this disorder. In both neoplasms, we have shown that the defective responses to cytokines are in some instances related to alterations in receptor expression, but this has not been true in all circumstances, and other stages in the signaling pathways are being investigated. As we define more precisely the specific defects that contribute to the clonal expansion of these neoplasms, the findings may ultimately lead to improved clinical control of these disorders.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9479579     DOI: 10.1007/BF02786442

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  35 in total

1.  CD4+ cutaneous T-cell lymphomas show the phenotype of helper/inducer T cells (CD45RA-, CDw29+).

Authors:  W Sterry; V Mielke
Journal:  J Invest Dermatol       Date:  1989-09       Impact factor: 8.551

2.  Immunolocalization of the ICE/Ced-3-family protease, CPP32 (Caspase-3), in non-Hodgkin's lymphomas, chronic lymphocytic leukemias, and reactive lymph nodes.

Authors:  S Krajewski; R D Gascoyne; J M Zapata; M Krajewska; S Kitada; M Chhanabhai; D Horsman; K Berean; L D Piro; I Fugier-Vivier; Y J Liu; H G Wang; J C Reed
Journal:  Blood       Date:  1997-05-15       Impact factor: 22.113

3.  Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation.

Authors:  M E McCusker; M Garifallou; S A Bogen
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

4.  Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia.

Authors:  J F DeCoteau; P I Knaus; H Yankelev; M D Reis; R Lowsky; H F Lodish; M E Kadin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

5.  Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta.

Authors:  R S Douglas; R J Capocasale; R J Lamb; P C Nowell; J S Moore
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

6.  Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders.

Authors:  L Trentin; A Cerutti; R Zambello; R Sancretta; C Tassinari; M Facco; F Adami; F Rodeghiero; C Agostini; G Semenzato
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

7.  Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.

Authors:  P Panayiotidis; K Ganeshaguru; S A Jabbar; A V Hoffbrand
Journal:  Br J Haematol       Date:  1993-11       Impact factor: 6.998

8.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

9.  Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation.

Authors:  S M Wahl; D A Hunt; H L Wong; S Dougherty; N McCartney-Francis; L M Wahl; L Ellingsworth; J A Schmidt; G Hall; A B Roberts
Journal:  J Immunol       Date:  1988-05-01       Impact factor: 5.422

10.  Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression.

Authors:  M Dancescu; M Rubio-Trujillo; G Biron; D Bron; G Delespesse; M Sarfati
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

View more
  1 in total

1.  Reduced IL-4 and interferon-gamma (IFN-gamma) expression by CD4 T cells in patients with chronic lymphocytic leukaemia.

Authors:  S J Hill; S H Peters; M J Ayliffe; J Merceica; A S Bansal
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.